

Table XXXI. CLARIVEN® variant

1 article, 1 RCT

Operative procedure	Reference	Summary
<p>CLARIVEIN® Various Sclerosing agent dose and form</p>	<p>Lam YL, Toonder IM, Wittens CHA. Clarivein® mechano-chemical ablation an interim analysis of a randomized controlled trial dose-finding study. <i>Phlebology</i>. 2016;31:170-176. DOI 10.1177:026835551 5599692</p>	<p>Multi-centre study. 87 symptomatic patients presenting primary GSV. Incompetence were enrolled. No data on SSV, no deep obstruction. Exclusion criteria: a history of previous surgery for ipsilateral GSV incompetence, GSV diameter > 12.0 mm. CEAP clinical classification C2-C4 All patients treated by Clarivein under local tumescent anesthesia. Postoperative compression by superposition of stockings class I and class II Group I (n=200) MOCA+2% Polidocanol Liquid <i>versus</i> Group II (n=200) MOCA+3% Polidocanol Liquid <i>versus</i> Group III (n=200) MOCA+1% Polidocanol Foam Results at 6 weeks of follow-up: . <i>GSV occlusion</i> Group I 100 % P= NS Group II 96.4% P<0.001 Group III 56.5%</p>

Abbreviations:

GSV= great saphenous vein; MOCA= mechanochemical ablation; SSV=small saphenous vein

